BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Cabot Corporation (NYSE: CBT) today announced that it has successfully completed its acquisition of Mexico Carbon Manufacturing S.A. de C.V. (MXCB) from Bridgestone Corporation. The transaction follows the announcement of a definitive agreement in August and the receipt of required regulatory approvals. Cabot has long supplied Bridgestone with reinforcing carbon products, and this acquisition further strengthens the partnership between the two companies. In additio ...

MONTREAL, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Ghislain Houle, Executive Vice-President and Chief Financial Officer of CN (TSX: CNR) (NYSE: CNI), will address Citi’s 2026 Global Industrial Tech and Mobility Conference on February 18, 2026, at 7:10 a.m. Eastern Time (ET). CN will provide a live webcast via the Investors section of its website at www.cn.ca/investors. A replay of the webcast will be available following the event. About CNCN powers the economy by safely transporting more than 300 million tons of n ...

RENO, Nev., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Plumas Bancorp (Nasdaq:PLBC) (the “Company”), the parent company of Plumas Bank, today announced that its Board of Directors has authorized a stock repurchase program under which the Company may repurchase up to $25 million of its outstanding common stock through the fourth quarter of 2026. Repurchases may be executed through open market purchases, privately negotiated transactions, block trades, or other means in accordance with applicable securities laws. The ...

LEAWOOD, Kan., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Euronet (NASDAQ: EEFT), a global leader in payments processing and cross-border transactions, announced today it will release its fourth quarter and full year 2025 earnings results prior to the market opening on Thursday, February 12, 2026. Euronet will hold a conference call on the same day at 9:00 a.m. Eastern Time to discuss the results. The conference call and accompanying slide show presentation will be accessible via webcast by following the link posted ...

The retail turnover (including VAT) of the Apranga Group amounted to EUR 28.2 million in January 2026 and increased by 9.1% compared to January 2025. In January 2026, the retail turnover of Apranga Group in Lithuania increased by 8.7% year-to-year, in Latvia grew by 8.5% and in Estonia improved by 12.3%. Currently Apranga Group operates the chain of 171 stores (103 in Lithuania, 44 in Latvia and 24 in Estonia) covering an area of 92.7 thousand sq. m. Stores area increased by 1.2% during the year. Rimantas P ...

CAMARILLO, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Qualstar Corporation (OTC: QBAK) (the “Company” or “Qualstar”), a trusted provider of scalable data storage and high-efficiency power solutions, announced the completion of its reincorporation from California to Nevada and a 3-for-1 forward split of its issued and outstanding common stock. The reincorporation and forward stock split have legally occurred, and the Company has submitted the required corporate action documentation with the Financial Industry ...

8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose re ...

Peer-Reviewed Imaging Across Multiple Indications Validates Nexalin’s Ability to Modulate Deep Brain Networks, Differentiating It from other Superficial Neurostimulation TechniquesHOUSTON, TX, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company” or “Nexalin”), the leader in non-invasive Deep Intracranial Frequency Stimulation (DIFS™) of the brain, today highlighted Nexalin’s rigorous peer-reviewed clinical research validating its proprietary neurostimulation technology acr ...

Core Insights - OptimumBank Holdings, Inc. reported net earnings of $4.85 million for Q4 2025, an increase from $4.32 million in Q3 2025 and $3.95 million in Q4 2024, driven by improved net interest income and noninterest income [1][15][22]. Financial Performance - Net interest income for Q4 2025 was $11.87 million, up from $11.05 million in Q3 2025 and $9.24 million in Q4 2024, supported by higher loan yields and lower costs on interest-bearing liabilities [5][17]. - Noninterest income decreased to $1.73 million in Q4 2025 from $1.98 million in Q3 2025, primarily due to fewer loan prepayment fees [6][22]. - Total noninterest expenses increased to $6.74 million in Q4 2025, compared to $6.60 million in Q3 2025 and $4.38 million in Q4 2024, reflecting higher employee compensation and marketing expenses [6][23][24]. Balance Sheet Highlights - Total assets grew to $1.11 billion as of December 31, 2025, up from $1.08 billion at September 30, 2025, and $932.93 million at December 31, 2024 [7][26]. - Total gross loans increased to $958.79 million at December 31, 2025, from $813.72 million at September 30, 2025, and $804.24 million at December 31, 2024, driven by growth in commercial and residential real estate [2][29]. - Total deposits decreased to $931.75 million at December 31, 2025, from $959.49 million at September 30, 2025, but increased from $772.20 million at December 31, 2024 [10][34]. Capital and Credit Quality - The allowance for credit losses was $10.27 million, or 1.07% of total loans, as of December 31, 2025, reflecting a well-managed loan portfolio [8][30]. - Nonaccrual loans decreased to $2.90 million at December 31, 2025, from $7.58 million at December 31, 2024, indicating improved asset quality [33]. Strategic Outlook - The Company plans to expand into new financial verticals that complement its banking operations, with a new subsidiary expected to launch in 2026 [5][12].

SEATTLE, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatments for cancers throughout the body, today announced the pricing of an underwritten offering of 39,576,088 shares of its common stock at an offering price of $3.79 per share and, to certain investors in lieu of common stock, pre-funded warrants to purchase 6,598,046 shares of its common stock at a price of $3.789 pe ...